The report reviews Cytotoxic T-Lymphocyte
Protein 4 (CTLA-4 or CD152) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
histocompatibility complex class I-related chain A-B; CTLA-4: cytotoxic T-lymphocyte
associated protein-4; PD-L1: programmed death-ligand 1; ICAM-1: intercellular adhesion molecule Figure 4: Summary of results on the presence of selected lineage- specific and vesicle-related markers on five leukocyte subpopulations and the corresponding leukocyte-derived sEVs.
The in vitro tumor-specific cytotoxic T-lymphocyte
(CTL) response elicited by immunization with mHSP/P was analyzed by means of lactate dehydrogenase release from damaged cells.
Computer-based design of an HLA-haplotype and HIV-clade independent cytotoxic T-lymphocyte
assay for monitoring HIV-specific immunity.
While the study remains blinded, cytotoxic T-lymphocyte
responses have been detected 16 of 116 volunteers, suggesting that the prime-boost approach may be appropriate for further clinical study.
Oral and intranasal insulin appear to be promising approaches, he said, since animal studies suggest that insulin delivered to the mucosa induces insulin antibodies, which in turn reduce cytotoxic T-lymphocyte
ICT-121 is IMUC's cancer stem cell vaccine that consists of a peptide to stimulate a Cytotoxic T-Lymphocyte
(CTL) response to CD-133, which is generally overexpressed on the cancer stem cells.
Recent efforts have focused on the use of recombinant DNA techniques to stimulate cytotoxic T-lymphocyte
Compared with the control patients, those in the STI group had significantly lower viral loads, higher CD4-positive T-cell counts, lower values of immune activation markers, and higher specific helper and cytotoxic T-lymphocyte
responses against HIV.
The study results showed that co-administration of PT-100 with a cytotoxic T-Lymphocyte
(CTL) peptide antigen and a T-cell helper peptide, administered either orally or intranasally, induced robust T cell responses which were dose dependent on PT-100.
Geron had previously shown in collaboration with researchers at Duke University that RNA encoding hTERT could be used to prime antigen presenting cells (DCs) ex vivo, and that these cells in turn could stimulate a potent, telomerase-specific cytotoxic T-lymphocyte
No other vaccine technology demonstrated to date has shown itself capable of inducing strong natural production of both highly specific neutralizing antibodies and a potent cytotoxic T-lymphocyte
(CTL) or cellular immune responses.